204 related articles for article (PubMed ID: 28063300)
1. A PSMA-targeted theranostic agent for photodynamic therapy.
Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG
J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300
[TBL] [Abstract][Full Text] [Related]
2. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
[TBL] [Abstract][Full Text] [Related]
4. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
Kiess AP; Minn I; Chen Y; Hobbs R; Sgouros G; Mease RC; Pullambhatla M; Shen CJ; Foss CA; Pomper MG
J Nucl Med; 2015 Sep; 56(9):1401-1407. PubMed ID: 26182968
[TBL] [Abstract][Full Text] [Related]
5. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
6. A low molecular weight PSMA-based fluorescent imaging agent for cancer.
Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG
Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734
[TBL] [Abstract][Full Text] [Related]
7.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen-targeted photoacoustic imaging of prostate cancer in vivo.
Zhang HK; Chen Y; Kang J; Lisok A; Minn I; Pomper MG; Boctor EM
J Biophotonics; 2018 Sep; 11(9):e201800021. PubMed ID: 29653029
[TBL] [Abstract][Full Text] [Related]
9. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
Derks YHW; Schilham MGM; Rijpkema M; Smeets EMM; Amatdjais-Groenen HIV; Kip A; van Lith SAM; van de Kamp J; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Heskamp S; Lütje S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2872-2884. PubMed ID: 37060367
[TBL] [Abstract][Full Text] [Related]
10. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
11. Porphyrin-grafted Lipid Microbubbles for the Enhanced Efficacy of Photodynamic Therapy in Prostate Cancer through Ultrasound-controlled
You Y; Liang X; Yin T; Chen M; Qiu C; Gao C; Wang X; Mao Y; Qu E; Dai Z; Zheng R
Theranostics; 2018; 8(6):1665-1677. PubMed ID: 29556348
[TBL] [Abstract][Full Text] [Related]
12. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.
Chen B; Pogue BW; Zhou X; O'Hara JA; Solban N; Demidenko E; Hoopes PJ; Hasan T
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):720-7. PubMed ID: 15701861
[TBL] [Abstract][Full Text] [Related]
13. The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents.
Mukai H; Wada Y; Watanabe Y
Ann Nucl Med; 2013 Aug; 27(7):625-39. PubMed ID: 23605059
[TBL] [Abstract][Full Text] [Related]
14. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway.
Liu T; Wu LY; Choi JK; Berkman CE
Int J Oncol; 2010 Apr; 36(4):777-84. PubMed ID: 20198319
[TBL] [Abstract][Full Text] [Related]
15. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
16. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
[TBL] [Abstract][Full Text] [Related]
17. Development and therapeutic evaluation of 5D3(CC-MLN8237)
Liatsou I; Assefa B; Liyanage W; Surasinghe S; Nováková Z; Bařinka C; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Front Pharmacol; 2024; 15():1385598. PubMed ID: 38751786
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
[TBL] [Abstract][Full Text] [Related]
19. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Choi JK; Berkman CE
Prostate; 2009 May; 69(6):585-94. PubMed ID: 19142895
[TBL] [Abstract][Full Text] [Related]
20. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA).
Banerjee SR; Pullambhatla M; Shallal H; Lisok A; Mease RC; Pomper MG
Oncotarget; 2011 Dec; 2(12):1244-53. PubMed ID: 22207391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
